<DOC>
	<DOCNO>NCT00024102</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give different way surgery may kill tumor cell . It yet know chemotherapy regimen effective treat old woman breast cancer . PURPOSE : This randomized phase III trial study different combination chemotherapy regimens see well work treat old woman undergo surgery breast cancer .</brief_summary>
	<brief_title>Comparison Combination Chemotherapy Regimens Treating Older Women Who Have Undergone Surgery Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effectiveness adjuvant chemotherapy comprise standard cyclophosphamide , methotrexate , fluorouracil ( CMF ) doxorubicin cyclophosphamide ( AC ) vs oral capecitabine , term disease-free overall survival , elderly woman operable adenocarcinoma breast . - Compare quality life physical functioning patient treat regimen . - Compare toxicity regimens patient . - Evaluate adherence old patient oral chemotherapy regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 65 69 v 70 80 v 80 ) , performance status ( 0-1 v 2 ) , HER2 status ( positive v negative v unknown ) . Patients randomize 1 2 treatment arm . - Arm I : Patients insufficient leave ventricular ejection fraction ( LVEF ) assign group A . Patients normal LVEF assign group A B base physician/patient choice . - Group A ( CMF ) : Patients receive oral cyclophosphamide ( CTX ) daily day 1-14 methotrexate IV fluorouracil IV day 1 8 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . - Group B ( AC ) : Patients receive doxorubicin IV CTX IV day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Arm II : Patients receive oral capecitabine twice daily day 1-14 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Beginning within 12 week treatment arm I II , patient estrogen progesterone receptor-positive disease receive oral tamoxifen aromatase inhibitor daily 5 year . Beginning 4-6 week treatment arm I II , eligible patient previously underwent breast conservation surgery undergo radiotherapy . Quality life assess baseline ; 6 week ( group B ) , 9 week ( arm II ) , 12 week ( group A ) ; 1 , 12 , 18 , 24 month study . Drug adherence assess 9 week study ( arm II ) . Patients follow 1 month , every 6 month 2 year , annually 15 year . PROJECTED ACCRUAL : A total 600-1,800 patient ( 300-900 per treatment arm ) accrue study within 2-6 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Patients operable , histologically confirm adenocarcinoma female breast . 2 . TNM Stage per AJCC Cancer Staging Manual 6th edition : T14 ( Tumor size &gt; 1 cm ) , N0 , M0 T14 , N13 , M0 Patients bilateral , synchronous breast cancer eligible long one primary tumor meet criteria . 3 . Patients HER2/neu positive , negative unknown disease eligible trial . Patients whose tumor HER2 positive either immunohistochemistry 3+ stain demonstrate gene amplification FISH eligible receive trastuzumab , outline protocol . 4 . Age 65 year old 5 . Performance status 02 ( Common Toxicity Criteria ) . 6 . Prior treatment : Surgical resection All tumor remove either modified radical mastectomy lumpectomy . Patients must register ≤ 84 day mastectomy within 84 day axillary dissection patient 's extensive breast surgery breast sparing procedure . Node dissection : Axillary node dissection require . Management axilla discretion treat physician . There restriction eligibility base number node remove . Mastectomy : There evidence gross microscopic invasive tumor surgical resection margin note final surgery pathology report patient modify radical mastectomy . Patients close margin ( tumor &lt; 1 mm margin ) eligible . Segmental mastectomy ( lumpectomy ) : Although clear margin preferable , DCIS LCIS surgical resection margin render patient undergone segmental mastectomy ineligible study . Invasive tumor final resection margin render patient ineligible . No prior chemotherapy malignancy . Patients history hypersensitivity 5FU know dihydropyrimidine dehydrogenase ( DPD ) deficiency eligible participate . Patients may receive four week tamoxifen therapy malignancy still eligible study entry . Patients receive tamoxifen raloxifene purpose chemoprevention ( e.g. , Breast Cancer Prevention Trial ) indication ( include previous breast cancer ) eligible . Tamoxifen raloxifene therapy discontinue patient enrol study . 7 . Required Initial Laboratory Data : Granulocytes &gt; 1,500/µl Platelet count ≥100,000/µl Calculated Creatinine Clearance &gt; 30 mL/min Total bilirubin ≤ ULN</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>